The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 2, 1998, Pages 216-222

  Neyts, Johan ^a   Andrei, Graciela ^a   De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; GANCICLOVIR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENCICLOVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESISTANCE; GROWTH RETARDATION; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; LUNG ALVEOLUS CELL; MOUSE; NONHUMAN; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION; VERO CELL; VIRUS INFECTION;

ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; DEOXYGUANINE NUCLEOTIDES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GANCICLOVIR; HERPES GENITALIS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, NUDE; MYCOPHENOLIC ACID; VERO CELLS;

EID: 0031952851     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Baba, M., R. Pauwels, J. Balzarini, P. Herdewijn, E. De Clercq, and J. Desmyter. 1987. Ribavirin antagonizes inhibitory effects of pyrimidine 2′,3′-dideoxynucleosides but enhances inhibitory effects of purine 2′,3′-clideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 31:1613-1617.
2. Balfour, H. H., Jr., C. Benson, J. Braun, B. Cassens, A. Erice, A. Friedman-Kien, T. Klein, B. Polsky, and S. Safrin. 1994. Management of acyclovirresistant herpes simplex and varicella-zoster virus infections. J. Acquired Immune Defic. Syndr. 7:254-260.
3. Balzarini, J., C.-K. Lee, D. Schols, and E. De Clercq. 1991. 1-α-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) and 5-ethynyl-1-α-D-ribofuranosylimidazole-4-carboxamide (EICAR) markedly potentiate the inhibitory effect of 2′,3′-dideoxyinosine on human immunodeficiency virus in peripheral blood lymphocytes. Biochem. Biophys. Res. Commun. 178:563-569.
4. Balzarini, J., C.-K. Lee, P. Herdewijn, and E. De Clercq. 1991. Mechanism of the potentiating effect of ribavirin on the activity of 2′,3′-dideoxyinosine against human immunodeficiency virus. J. Biol. Chem. 266:21509-21514.
5. Balzarini, J., L. Naesens, M. Robins, and E. De Clercq. 1990. Potentiating effect of ribavirin on the in vitro and in vivo antiretrovirus activities of 2′,3′-dideoxyinosine and 2′,3′-dideoxy-2,6-diaminopurine riboside. J. Acquired Immune Defic. Syndr. 3:1140-1147.
6. Boyd, M. R., S. Safrin, and E. R. Kern. 1993. Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern. Antiviri. Chem. Chemother. 4(Suppl. 1):3-11.
7. Bullingham, R., S. Monroe, A. Nicholls, and M. Hale. 1996. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J. Clin. Pharmacol. 36:315-324.
8. De Clercq, E. 1995. Trends in the development of new antiviral agents for the chemotherapy of infections caused by herpesviruses and retroviruses. Rev. Med. Virol. 5:149-164.
9. De Clercq, E., J. Descamps, G. Verhelst, R. T. Walker, A. S. Jones, P. F. Torrence, and D. Shugar. 1980. Comparative efficacy of different antiherpes drugs against different strains of herpes simplex virus. J. Infect. Dis. 141: 563-574.
10. Field, H. J., D. Tewari, D. Sutton, and A. M. Thackray. 1995. Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model. Antimicrob. Agents Chemother. 39: 1114-1119.
11. Field, H. J., and A. M. Thackray. 1995. The effects of delayed-onset chemotherapy using famciclovir or valaciclovir in a murine immunosuppression model for HSV-1. Antivir. Chem. Chemother. 6:210-216.
12. Fulton, B., and A. Markham. 1996. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 51:278-298.
13. Hartman, N. R., G. S. Ahluwalia, D. A. Cooney, H. Mitsuya, S. Kageyama, A. Fridland, S. Broder, and D. G. D. A. Johns. 1991. Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine. Mol. Pharmacol. 40:118-124.
14. Johns, D. G., G. S. Ahluwalia, D. A. Cooney, H. Mitsuya, and J. S. Driscoll. 1993. Enhanced stimulation by ribavirin of the 5′-phosphorylation and antihuman immunodeficiency virus activity of purine 2′-β-fluoro-2′,3′-dideoxynucleosides. Mol. Pharmacol. 44:519-523.
15. Keller, P. M., S. A. McKee, and J. A. Fyfe. 1985. Cytoplasmic 5′-nucleotidase catalyzes acyclovir phosphorylation. J. Biol. Chem. 260:8664-8667.
16. Kletzmayr, J., H. Kotzmann, T. Popow-Kraupp, J. Kovarik, and R. Klauser. 1996. Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients. J. Am. Soc. Nephrol. 7:325-330.
17. Lake, K. D., and D. M. Canafax. 1995. Important interactions of drugs with immunosuppressive agents used in transplant recipients. J. Antimicrob. Chemother. 36(Suppl. B): 11-22.
18. Patel, R. 1996. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 61:1279-1289.
19. Ransom, J. T. 1995. Mechanism of action of mycophenolate mofetil. Ther. Drug Monit. 17:681-684.
20. Safrin, S., T. Elbeik, L. Phan, D. Robinson, J. Rush, A. Elbaggari, and J. Mills. 1994. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 38:1246-1250.
21. Snoeck, R., G. Andrei, E. De Clercq, M. Gerard, N. Clumeck, G. Tricot, and C. Sadzot-Delvaux. 1993. A new topical treatment for resistant herpes simplex infections. N. Engl. J. Med. 329:968-969.
22. Snoeck, R., G. Andrei, M. Gérard, A. Silverman, A. Hedderman, J. Balzarini, C. Sadzol-Delvaux, G. Tricot, N. Clumeck, and E. De Clercq. 1994. Successful treatment of progressive mucocutaneous infection due to acyclovir-and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC). Clin. Infect. Dis. 18:570-578.
23. Suthanthiran, M., R. E. Morris, and T. B. Strom. 1996. Immunosuppressants: cellular and molecular mechanisms of action. Am. J. Kidney Dis. 28:159-172.
24. Zaia, J. A. 1996. Prophylaxis and treatment of CMV infections in transplantation. Adv. Exp. Med. Biol. 394:117-134.